The general rule of thumb for rejected leases in BK is the the landlord is entitled to 15% of the remaining lease payments - the rule is worded differently - but that's approximately how it works out.
I've been following MBRKQ quite closely. I believe the value lies not in their 2 approved drugs but in their PULSYS platform. If you want to google around - look up 'pulsatile drug delivery systems' and variants thereof. Its a new and growing niche in the pharma space, largely due to a lack of good time release formulations on the market. MBRK under its prior name was really a pioneer in the area, so their patent estate is very good. They also have one of the first pulsatile drugs to get FDA approval. Unfortunately for MBRK, it (moxatag - a antibiotic) wasn't in a space where the benefits of really good once a day justified the higher price. Some still think the value is in Mox or their Keflex drug - I think its all about the underlying IP, in which case overbidding could be a real possibility. The other area to google is 'evergreening patents' - taking a blockbuster near the end of its patent protection cycle and putting it into a new formulation wins you extra years of monopoly - Pulsys is a nice value added application for the industry in this respect as well (sepearate and apart from its claims to deliver less dosage more effectively - if only they had a MRSA drug to attach to their pill).
News 
Market Data 
Discover 
AI
